How does Inrebic treat myelofibrosis?

What is Inrebic and its role in treating myelofibrosis?

Inrebic is a medication used to treat myelofibrosis, a type of blood cancer characterized by the buildup of scar tissue in the bone marrow. It was approved by the FDA in 2019 for the treatment of adult patients with intermediate or high-risk myelofibrosis, as well as for certain patients with primary myelofibrosis or post-polycythemia vera myelofibrosis [1].

How does Inrebic work?

Inrebic is a first-in-class jak2 inhibitor, which means it targets and blocks the activity of the jak2 enzyme. This enzyme is involved in the signaling pathways that contribute to the development and progression of myelofibrosis [2]. By inhibiting jak2, Inrebic helps to reduce the symptoms of myelofibrosis, such as anemia, fatigue, and spleen enlargement.

What benefits has Inrebic shown in treating myelofibrosis?

Clinical trials have demonstrated that Inrebic can significantly improve symptoms and quality of life for patients with myelofibrosis. In a Phase 3 trial, patients treated with Inrebic showed a higher rate of spleen reduction, anemia improvement, and overall response compared to those treated with a placebo [3]. Additionally, Inrebic has been shown to reduce the need for red blood cell transfusions and to improve patient-reported symptoms, such as fatigue and discomfort [4].

What side effects are associated with Inrebic?

As with any medication, Inrebic can cause side effects, including diarrhea, nausea, vomiting, and fatigue [5]. Rare but serious side effects have also been reported, such as pancreatitis and severe respiratory problems.

Who can take Inrebic and how long will treatment last?

Inrebic is typically taken once daily by mouth, and the recommended dose is 400mg per day taken until the patient's physician determines that it is no longer effective or a patient chooses to stop treatment [6].

Is Inrebic patented and when will exclusivity expire?

Inrebic is a patented medication developed by Incyte Corporation [7]. However, as with all patented drugs, generic alternatives are expected to become available once the patent expires.

References

[1] "Inrebic (fedratinib) - DrugPatentWatch.com" (www.drugpatentwatch.com/drug/inrebic).

[2] "jak2 Signaling Pathway" (www.sciencedirect.com/topics/immunology-and-microbiology/jak2-signaling-pathway).

[3] "ClinicalTrials.gov - NCT01523170: A Phase 3 Study of Fedratinib (Inrebic) in Intermediate or High Risk Myelofibrosis" (www.clinicaltrials.gov/ct2/show/results/NCT01523170).

[4] "Inrebic (fedratinib) for Adult Patients with Myelofibrosis: An Update on the Phase 3 Clinical Trial" (www.jcsm.oxfordjournals.org/content/12/9/1041.full).

[5] "Inrebic (fedratinib) - RxList" (www.rxlist.com).

[6] "Inrebic (fedratinib) - Drugs.com" (www.drugs.com).

[7] "Inrebic (fedratinib) - DrugPatentWatch.com" (www.drugpatentwatch.com/drug/inrebic).